Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
3 results about "Mumpsvax" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mumpsvax is a mumps vaccine made of mumps virus. Mumpsvax is a product of Merck & Co.,Inc. The vaccine is a component of Merck's three-virus MMR vaccine. Mumpsvax is administered by a subcutaneous injection of live virus reconstituted from freeze-dried vaccine. The dosage of the mumps vaccine component in MMR is the same as of Mumpsvax, "Each 0.5 mL dose contains not less than 20,000 TCID₅₀ of mumps virus." The Merck product information recommends MMR as the secondary vaccination treatment with Mumpsvax. Mumpsvax is produced from the Jeryl Lynn strain of mumps virus developed by Maurice Hilleman. When his daughter Jeryl Lynn Hilleman contracted Mumps Dr. Hilleman cultured the vaccine strain from her throat. The mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production.